Working… Menu

Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing Facility

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00627692
Recruitment Status : Completed
First Posted : March 3, 2008
Last Update Posted : May 29, 2008
Information provided by:

Brief Summary:

The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of constipation in elderly subjects living in a nursing facility.


Prucalopride up to a dose of 4 mg once daily is safe and well tolerated in in elderly subjects living in a nursing facility.

Condition or disease Intervention/treatment Phase
Constipation Drug: Prucalopride Other: Placebo Phase 2

Detailed Description:

This is a multicenter, Phase II, dose-escalation trial with a 4 week double-blind, placebo-controlled treatment period. There will be four treatment cohorts (0.5 mg, 1 mg, 2 mg, or 4 mg) with 25 subjects in each. The first cohort of 25 subjects will be randomly assigned to receive either 0.5 mg R108512 or placebo in a 4 to 1 ratio, respectively, for four weeks. After two weeks of treatment, the safety and tolerability of this dose will be evaluated for each subject by an independent (external) safety committee. If, at the completion of treatment, the safety committee grants approval to proceed to a higher dose, the second cohort will be randomly assigned to receive either 1 mg R108512 or placebo for four weeks. In a likewise manner, each dose will be evaluated for safety and tolerability before the next cohort will be treated with a higher dose. No subject can participate in more than one treatment cohort.

Subjects will be instructed not to change their diet or lifestyle during the trial. Subjects will be allowed to continue the use of routine stool softeners and fiber supplements during the trial; however, all existing stimulant or osmotic laxative medication will be withdrawn. If, during the trial, the subject does not have a complete bowel movement for three or more consecutive days, he/she will be allowed the use of his/her usual stimulant or osmotic laxative or an enema as a rescue medication. No laxatives or enemas should be used within the 24 hours before and 24 hours after the start of double-blind treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Oral Once-Daily Prucalopride (R108512) Solution in Constipated Elderly Subjects Living in a Nursing Facility
Study Start Date : February 1999
Actual Primary Completion Date : May 2000
Actual Study Completion Date : May 2000

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation

Arm Intervention/treatment
Active Comparator: 1
Drug: Prucalopride
0.5 mg o.d.
Other Name: Resolor

Active Comparator: 2
Drug: Prucalopride
1 mg o.d.
Other Name: Resolor

Active Comparator: 3
Drug: Prucalopride
2 mg o.d.
Other Name: Resolor

Placebo Comparator: 5
Other: Placebo

Active Comparator: 4
Drug: Prucalopride
4 mg o.d.
Other Name: Resolor

Primary Outcome Measures :
  1. Patient's Global Assessment of severity of constipation and efficacy of treatment evaluated (for exploratory reasons only). [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Patient's symptom assessment(evaluated for exploratory reasons only). [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female patients at least 65 years of age (no upper age limit).
  2. History of constipation. i.e., the patient should have received any treatment for constipation at any time during the 4 weeks (28 days) preceding entry into the study, including fibre/bulk forming supplements.
  3. The patient had to live in a nursing facility.
  4. The patient had to be clinically stable.
  5. The patient had to be able to take oral medications.
  6. The patient had to be continent of bowels the majority of time.
  7. The patient had to be able to reliably communicate AEs.
  8. The patient had to provide informed consent, signed by the patient or legally acceptable representative and by the investigator.

Exclusion Criteria:

  1. Patients who were known to be HIV positive or who had AIDS.
  2. Patients who were being actively treated with Propulsid (cisapride) or cancer chemotherapy other than hormonal agents.
  3. Patients with significantly impaired renal function, i.e., creatinine clearance <30 mL/min using the Cockcroft and Gault formula:

    Males: CLCR = [(140-age) x (weight in kg)] / 72 x (SCR).

    Females: CLCR = male value x 0.85

    Because the calculated value for creatinine clearance could be artificially high when serum creatinine concentrations were very low, patients with a serum creatinine <0.5 mg/dL were excluded from the study.

  4. Patients who received an investigational drug in the 30 days preceding the study.
  5. Patients who had previously received either R093877 or R108512.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00627692

Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: D O'Neill, MD Riverside Regional Convalescent Center

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Renate Specht Gryp, Movetis Identifier: NCT00627692     History of Changes
Other Study ID Numbers: PRU-USA-26
First Posted: March 3, 2008    Key Record Dates
Last Update Posted: May 29, 2008
Last Verified: January 2008
Keywords provided by Movetis:
Constipation in elderly patients
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Signs and Symptoms
Gastrointestinal Agents
Serotonin 5-HT4 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs